Premium
Phase II study of S‐1 and irinotecan combination chemotherapy as a first‐line therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05‐02
Author(s) -
KANG Hye J,
CHO Sang H,
OH Suk J,
YANG Sung H,
LEE Moon H,
SONG EunKee,
CHUNG Hyun C,
NA Im I,
RYOO BaekYeol
Publication year - 2009
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2009.01191.x
Subject(s) - irinotecan , medicine , neutropenia , chemotherapy , gastroenterology , cancer , adverse effect , vomiting , combination chemotherapy , combination therapy , nausea , common terminology criteria for adverse events , oncology , surgery , colorectal cancer
Background: Irinotecan plus intravenous 5‐fluorouracil (5‐FU) with leucovorin is effective against gastrointestinal cancer. S‐1 is an oral fluoropyrimidine derivative and has a high response rate of about 40% for patients with advanced gastric cancer (AGC). We evaluated the antitumor activity and toxicities of an S‐1 and irinotecan combination as a first‐line therapy for patients with AGC. Methods: Patients with histologically confirmed unresectable or metastatic AGC were treated with S‐1 40 mg/m 2 PO twice daily on days 1–14 and irinotecan 150 mg/m 2 i.v. on day 1 every 3 weeks until disease progression or unacceptable toxicities resulted. Results: A total of 45 patients were enrolled between September 2005 and March 2007. After a median of seven cycles of chemotherapy (range: 1–20, total: 350), 42 and 44 patients were evaluable for response and toxicity, respectively. On the intention‐to‐treat analysis, the overall response rate was 48.9% (95% C.I. 34.3–63.5%). The median time to progression was 5.7 months (95% C.I. 4.3–7.1) and the median overall survival was 10.4 months (95% C.I. 6.1–14.7). The commonly observed grade 3/4 adverse events were neutropenia (29.5% of patients) and vomiting (13.6%). Conclusion: An S‐1 and irinotecan combination chemotherapy is active and tolerable as a first‐line therapy for AGC.